Related Business Topics
Latest Headlines
Reuters - Nov. 16, 2009, 11:15 AM
Responses Demonstrated in Leukemia and Ovarian Cancer Patients ROCKVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced ...
Forbes.com - Nov. 3, 2009, 5:14 AM
ROCKVILLE, Md. (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO -- Poster Session: Monday, November 16, 2009 About ENMD-2076 ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and ...
Forbes.com - Oct. 22, 2009, 6:03 AM
BusinessWire - --REVLIMID(R) Third Quarter Global Sales Increased 31% Y/Y and 13% Q/Q --REVLIMID U.S. Total Share Increased to Approximately 34%; Strong Share Gains in Second and Third Lines of Therapy in Europe --VIDAZA(R) Third Quarter Global Sales ...
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
E
EntreMed
EntreMed's mission as the Angiogenesis company is to discover, develop and commercialize antiangiogenic therapeutics which have the potential to treat diseases associated with angiogenesis including cancer and blindness.
www.entremed.com
EntreMed's mission as the Angiogenesis company is to discover, develop and commercialize antiangiogenic therapeutics which have the potential to treat diseases associated with angiogenesis including cancer and blindness.
www.entremed.com
